Pubmed ID: 29610832

Journal: Annals of internal medicine

Publication Date: June 19, 2018

Affiliation: University of California, San Francisco, San Francisco, California (D.S.K., J.P., P.G.C., K.B.).

MeSH Terms: Humans, Adult, Aged, Aged, 80 and over, Cardiovascular Diseases, Middle Aged, Cost-Benefit Analysis, Hypolipidemic Agents, Drug Costs, Proprotein Convertase 9, Outcome and Process Assessment, Health Care, PCSK9 Inhibitors, Protease Inhibitors

Authors: Bibbins-Domingo K, Coxson PG, Penko J, Kazi DS, Ollendorf DA

Cite As: Kazi DS, Penko J, Ollendorf DA, Coxson PG, Bibbins-Domingo K. Effect of Money-Back Guarantees on the Cost-Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors. Ann Intern Med 2018 Jun 19;168(12):896-898. Epub 2018 Apr 3.

Studies:

• Framingham Heart Study (FHS)
• Framingham Heart Study-Cohort (FHS-Cohort)